ArticleBMC cancer2026
Molecular markers for cervical cancer prognosis: a prognostic model using stemness-related lncRNAs and functional analysis of EMX2OS.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCancer stemness-related long non-coding RNAs (lncRNAs) play a crucial role in tumor initiation and progression. This study aimed to identify stemness-related lncRNAs in cervical cancer (CESC) and evaluate the prognostic significance, clinical relevance, and biological functions. MATERIALS &
methodsTranscriptome data from the Cancer Genome Atlas were used to construct a co-expression network of cancer stemness-related genes and CESC-specific lncRNAs, focusing on cervical squamous cell carcinoma and endocervical adenocarcinoma. Identified stemness-related lncRNAs were used to develop a prognostic model through univariate, LASSO, and multivariate Cox regression analyses. Quantitative real-time PCR and in situ hybridization were performed to measure EMX2OS expression in normal and cancerous cervical tissues. Statistical tests were applied to analyze the association between EMX2OS expression and clinicopathological features. The effects of EMX2OS overexpression on cell proliferation, migration, and invasion were investigated using using the Cell Counting Kit-8 (CCK-8) assay, 5-ethynyl-2’-deoxyuridine (EdU) assay, plate cloning assay, wound healing assay, and transwell assays.
resultsA prognostic model comprising five lncRNAs (FOXD3-AS1, KCNMB2-AS1, EMX2OS, LINC02446, SOCS2-AS1) was developed, demonstrating robust prognostic performance. EMX2OS expression was significantly down-regulated in CESC tissues compared to normal tissues. In situ hybridization showed a marked association between EMX2OS expression and tumor size (P = 0.005), depth of stromal invasion (P = 0.009), and 5-year survival status (P = 0.003). The 5-year survival rate was significantly lower in the low expression group (P = 0.006). Overexpression of EMX2OS significantly suppressed cell proliferation, migration, and invasion.
conclusionsThe prognostic model based on 5 lncRNAs reflecting the stemness of CESC stem cells can reliably predict the prognosis of patients with CESC. Additionally, EMX2OS serves as a significant tumor suppressor marker in CESC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.